vs
GLACIER BANCORP, INC.（GBCI）与Ultragenyx Pharmaceutical Inc.（RARE）财务数据对比。点击上方公司名可切换其他公司
GLACIER BANCORP, INC.的季度营收约是Ultragenyx Pharmaceutical Inc.的1.5倍（$306.8M vs $207.3M），GLACIER BANCORP, INC.净利率更高（26.8% vs -62.0%，领先88.8%），过去两年Ultragenyx Pharmaceutical Inc.的营收复合增速更高（38.0% vs 24.3%）
Glacier Bancorp, Inc.是美国区域性多银行控股公司，总部位于蒙大拿州卡利斯佩尔，前身为1990年在特拉华州注册成立的企业。集团面向个人及商业客户提供各类银行服务，在全美8个州共设有221个营业网点。
Ultragenyx Pharmaceutical Inc.是一家总部位于美国的生物制药企业，专注于研发罕见病和超罕见遗传病的创新治疗方案，这类疾病目前大多无获批疗法，存在大量未被满足的临床需求。公司覆盖生物制剂、小分子药物、基因疗法、反义寡核苷酸及mRNA等多种药物技术平台，研发管线涵盖骨骼、内分泌、代谢、肌肉及中枢神经系统疾病领域。
GBCI vs RARE — 直观对比
营收规模更大
GBCI
是对方的1.5倍
$207.3M
净利率更高
GBCI
高出88.8%
-62.0%
两年增速更快
RARE
近两年复合增速
24.3%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $306.8M | $207.3M |
| 净利润 | $82.1M | $-128.6M |
| 毛利率 | — | — |
| 营业利润率 | — | -54.7% |
| 净利率 | 26.8% | -62.0% |
| 营收同比 | — | 25.9% |
| 净利润同比 | — | 3.5% |
| 每股收益（稀释后） | $0.63 | $-1.28 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收GBCIRARE
| Q1 26 | $306.8M | — | ||
| Q4 25 | $306.5M | $207.3M | ||
| Q3 25 | $260.7M | $159.9M | ||
| Q2 25 | $240.6M | $166.5M | ||
| Q1 25 | $222.6M | $139.3M | ||
| Q4 24 | $223.0M | $164.6M | ||
| Q3 24 | $214.9M | $139.5M | ||
| Q2 24 | $198.7M | $147.0M |
净利润GBCIRARE
| Q1 26 | $82.1M | — | ||
| Q4 25 | $63.8M | $-128.6M | ||
| Q3 25 | $67.9M | $-180.4M | ||
| Q2 25 | $52.8M | $-115.0M | ||
| Q1 25 | $54.6M | $-151.1M | ||
| Q4 24 | $61.8M | $-133.2M | ||
| Q3 24 | $51.1M | $-133.5M | ||
| Q2 24 | $44.7M | $-131.6M |
营业利润率GBCIRARE
| Q1 26 | — | — | ||
| Q4 25 | 24.9% | -54.7% | ||
| Q3 25 | 32.7% | -106.9% | ||
| Q2 25 | 27.1% | -64.8% | ||
| Q1 25 | 28.5% | -102.6% | ||
| Q4 24 | 33.0% | -74.3% | ||
| Q3 24 | 28.9% | -94.6% | ||
| Q2 24 | 27.3% | -79.1% |
净利率GBCIRARE
| Q1 26 | 26.8% | — | ||
| Q4 25 | 20.8% | -62.0% | ||
| Q3 25 | 26.0% | -112.8% | ||
| Q2 25 | 21.9% | -69.0% | ||
| Q1 25 | 24.5% | -108.5% | ||
| Q4 24 | 27.7% | -80.9% | ||
| Q3 24 | 23.8% | -95.7% | ||
| Q2 24 | 22.5% | -89.5% |
每股收益（稀释后）GBCIRARE
| Q1 26 | $0.63 | — | ||
| Q4 25 | $0.49 | $-1.28 | ||
| Q3 25 | $0.57 | $-1.81 | ||
| Q2 25 | $0.45 | $-1.17 | ||
| Q1 25 | $0.48 | $-1.57 | ||
| Q4 24 | $0.55 | $-1.34 | ||
| Q3 24 | $0.45 | $-1.40 | ||
| Q2 24 | $0.39 | $-1.52 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $1.4B | $421.0M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $4.2B | $-80.0M |
| 总资产 | $31.7B | $1.5B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资GBCIRARE
| Q1 26 | $1.4B | — | ||
| Q4 25 | — | $421.0M | ||
| Q3 25 | — | $202.5M | ||
| Q2 25 | — | $176.3M | ||
| Q1 25 | — | $127.1M | ||
| Q4 24 | — | $174.0M | ||
| Q3 24 | — | $150.6M | ||
| Q2 24 | — | $480.7M |
股东权益GBCIRARE
| Q1 26 | $4.2B | — | ||
| Q4 25 | $4.2B | $-80.0M | ||
| Q3 25 | $3.6B | $9.2M | ||
| Q2 25 | $3.5B | $151.3M | ||
| Q1 25 | $3.3B | $144.2M | ||
| Q4 24 | $3.2B | $255.0M | ||
| Q3 24 | $3.2B | $346.8M | ||
| Q2 24 | $3.1B | $432.4M |
总资产GBCIRARE
| Q1 26 | $31.7B | — | ||
| Q4 25 | $32.0B | $1.5B | ||
| Q3 25 | $29.0B | $1.2B | ||
| Q2 25 | $29.0B | $1.3B | ||
| Q1 25 | $27.9B | $1.3B | ||
| Q4 24 | $27.9B | $1.5B | ||
| Q3 24 | $28.2B | $1.5B | ||
| Q2 24 | $27.8B | $1.6B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $-99.8M |
| 自由现金流经营现金流 - 资本支出 | — | $-100.8M |
| 自由现金流率自由现金流/营收 | — | -48.6% |
| 资本支出强度资本支出/营收 | — | 0.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-472.0M |
8季度趋势，按日历期对齐
经营现金流GBCIRARE
| Q1 26 | — | — | ||
| Q4 25 | $374.4M | $-99.8M | ||
| Q3 25 | $112.4M | $-91.4M | ||
| Q2 25 | $86.0M | $-108.3M | ||
| Q1 25 | $52.4M | $-166.5M | ||
| Q4 24 | $258.0M | $-79.3M | ||
| Q3 24 | $150.1M | $-67.0M | ||
| Q2 24 | $62.7M | $-77.0M |
自由现金流GBCIRARE
| Q1 26 | — | — | ||
| Q4 25 | $347.6M | $-100.8M | ||
| Q3 25 | $104.8M | $-92.7M | ||
| Q2 25 | $79.5M | $-110.7M | ||
| Q1 25 | $46.8M | $-167.8M | ||
| Q4 24 | $209.8M | $-79.5M | ||
| Q3 24 | $137.7M | $-68.6M | ||
| Q2 24 | $44.1M | $-79.0M |
自由现金流率GBCIRARE
| Q1 26 | — | — | ||
| Q4 25 | 113.4% | -48.6% | ||
| Q3 25 | 40.2% | -58.0% | ||
| Q2 25 | 33.1% | -66.5% | ||
| Q1 25 | 21.0% | -120.5% | ||
| Q4 24 | 94.1% | -48.3% | ||
| Q3 24 | 64.1% | -49.2% | ||
| Q2 24 | 22.2% | -53.7% |
资本支出强度GBCIRARE
| Q1 26 | — | — | ||
| Q4 25 | 8.8% | 0.5% | ||
| Q3 25 | 2.9% | 0.8% | ||
| Q2 25 | 2.7% | 1.5% | ||
| Q1 25 | 2.5% | 1.0% | ||
| Q4 24 | 21.6% | 0.1% | ||
| Q3 24 | 5.8% | 1.2% | ||
| Q2 24 | 9.3% | 1.4% |
现金转化率GBCIRARE
| Q1 26 | — | — | ||
| Q4 25 | 5.87× | — | ||
| Q3 25 | 1.66× | — | ||
| Q2 25 | 1.63× | — | ||
| Q1 25 | 0.96× | — | ||
| Q4 24 | 4.18× | — | ||
| Q3 24 | 2.94× | — | ||
| Q2 24 | 1.40× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
GBCI
| Net Interest Income | $268.7M | 88% |
| Noninterest Income | $38.1M | 12% |
RARE
| Royalty | $105.6M | 51% |
| Products | $101.7M | 49% |
